Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 0752

Next Previous
X
Search
Drug Profile

MK 0752

Alternative Names: MK-0752

Latest Information Update: 03 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Cancer Research UK; Merck & Co
  • Class Antidementias; Antineoplastics; Propionates; Small molecules; Sulfones
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Breast cancer; CNS cancer; Haematological malignancies; Pancreatic cancer; Solid tumours

Most Recent Events

  • 03 Jun 2022 Discontinued - Phase-I for Breast cancer (Early-stage disease, Neoadjuvant therapy) in USA (PO) (Merck & Co. pipeline, June 2022)
  • 03 Jun 2022 Discontinued - Phase-I for Breast cancer (Late-stage disease) in USA (PO) (Merck & Co. pipeline, June 2022)
  • 03 Jun 2022 Discontinued - Phase-I for CNS cancer (In adolescents, In children) in USA (PO) (Merck & Co. pipeline, June 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top